Generate Biomedicines, Inc. Common Stock Cash Flow Conversion Efficiency
Generate Biomedicines, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Generate Biomedicines, Inc. Common Stock (GENB) has a cash flow conversion efficiency ratio of -0.127x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-57.94 Million) by net assets ($456.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Generate Biomedicines, Inc. Common Stock (2024–2025)
Cash flow conversion efficiency of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. This chart illustrates how Generate Biomedicines, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Generate Biomedicines, Inc. Common Stock (GENB) share price today for real-time trading data and today's change.
Generate Biomedicines, Inc. Common Stock Cash Flow Conversion Ratio Explained
Generate Biomedicines, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Generate Biomedicines, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Generate Biomedicines, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Generate Biomedicines, Inc. Common Stock (GENB) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gelsenwasser AG
F:WWG
|
0.031x |
|
Sinda Ltd.
NYSE:SIND
|
-0.291x |
|
BrightGene Bio Medical Technology C
SHG:688166
|
0.010x |
|
UIE PLC
CO:UIE
|
0.044x |
|
Veris Residential Inc
NYSE:VRE
|
0.011x |
|
Blackstone Mortgage Trust Inc
NYSE:BXMT
|
0.050x |
|
CHN Energy Changyuan Electric Power Co Ltd
SHE:000966
|
0.086x |
|
Argan SA
PA:ARG
|
0.038x |
Annual Cash Flow Conversion Efficiency for Generate Biomedicines, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Generate Biomedicines, Inc. Common Stock from 2024 to 2025. Review financial agility of Generate Biomedicines, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-623.20 Million | $-200.62 Million | 0.322x | +18.95% |
| 2024-12-31 | $-435.09 Million | $-117.75 Million | 0.271x | -- |
About Generate Biomedicines, Inc. Common Stock
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is … Read more